Krane Funds Advisors LLC Has $388,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Krane Funds Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 438 shares of the company’s stock after buying an additional 19 shares during the quarter. Krane Funds Advisors LLC’s holdings in Eli Lilly and Company were worth $388,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. CGN Advisors LLC grew its stake in Eli Lilly and Company by 1.4% in the 1st quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock valued at $779,000 after buying an additional 14 shares during the last quarter. Central Valley Advisors LLC bought a new stake in Eli Lilly and Company in the 1st quarter valued at $245,000. Annex Advisory Services LLC raised its stake in shares of Eli Lilly and Company by 14.1% in the 1st quarter. Annex Advisory Services LLC now owns 4,332 shares of the company’s stock valued at $3,370,000 after buying an additional 535 shares in the last quarter. Fermata Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 27.8% during the 1st quarter. Fermata Advisors LLC now owns 1,113 shares of the company’s stock worth $866,000 after acquiring an additional 242 shares during the period. Finally, Dynamic Advisor Solutions LLC boosted its position in shares of Eli Lilly and Company by 2.8% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,381 shares of the company’s stock valued at $11,966,000 after acquiring an additional 417 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.3 %

Shares of Eli Lilly and Company stock opened at $906.13 on Tuesday. The business’s 50 day simple moving average is $921.65 and its 200 day simple moving average is $859.57. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The firm has a market cap of $861.19 billion, a PE ratio of 133.45, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.